Open AccessNew guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China ☆
Author(s) -
Hu DaYi
Publication year - 2017
Publication title -
chronic diseases and translational medicine
Language(s) - English
Resource type - Journals
ISSN - 2589-0514
DOI - 10.1016/j.cdtm.2016.11.001
Subject(s) - medicine , dyslipidemia , guideline , public health , hyperlipidemia , china , family medicine , alternative medicine , disease , political science , law , pathology , diabetes mellitus , endocrinology
The “2016 Chinese guideline for the management of dyslipidemia in adults” (the new Guide for short) released by Zhonghua Xin Xue Guan Bing Za Zhi is based on the 2007 “Guide for Dyslipidemia Prevention in Chinese Adults” (the 2007 Hyperlipidemia Guide for short) and is the result of a year's effort and work by a team of specialists. The public release of the 2007 Hyperlipidemia Guide has had a positive effect on control and management of hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD). In the past decade, there has been a paradigm shift in international and domestic research and the viewpoints in this field; thus, a new guide for dyslipidemia is imperative. The group of specialists who have formulated the guides, from the 1997 “Recommendations for Dyslipidemia Prevention” to the first dyslipidemia guideline in China, until the formulation of this new Guide, have adhered to three principles. First, they used international guides as a reference with an emphasis on the data and